-
Mashup Score: 4
Focused on significant, underserved population unable to maximize or tolerate statins Nearly 14,000 patients in 32 countries Nearly half of the patients were women Primary Endpoint (MACE-4) Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization Hierarchy of Secondary…
Source: esperionscience.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4
Focused on significant, underserved population unable to maximize or tolerate statins Nearly 14,000 patients in 32 countries Nearly half of the patients were women Primary Endpoint (MACE-4) Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization Hierarchy of Secondary…
Source: esperionscience.comCategories: General Medicine News, CardiologistsTweet-
Check out all of our science differentiating our oral LDL-c lowering therapies @CircAHA @AHAScience and at https://t.co/YWwMtGV9pr 🫀👏👏👏👏👏 #CLEAROutcomes https://t.co/xzi1LUdh0j
-
-
Mashup Score: 4
Focused on significant, underserved population unable to maximize or tolerate statins Nearly 14,000 patients in 32 countries Nearly half of the patients were women Primary Endpoint (MACE-4) Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization Hierarchy of Secondary…
Source: esperionscience.comCategories: General Medicine News, CardiologistsTweet-
Check out all of our science differentiating our oral LDL-c lowering therapies @CircAHA @AHAScience and at https://t.co/YWwMtGV9pr 🫀👏👏👏👏👏 #CLEAROutcomes https://t.co/xzi1LUdh0j
-
-
Mashup Score: 1Pipeline – Esperion Science - 1 year(s) ago
Next Gen ACLY InhibitorInvestigational Stage ATP-citrate lyase (ACLY) is an enzyme strategically positioned at the intersection of nutrient catabolism and cholesterol and fatty acid biosynthesis. Esperion Therapeutics is leading the investigation of ACLY biology. While preclinical studies and Mendelian randomized trials support a causal role for ACLY in dyslipidemia and ASCVD, they also…
Source: esperionscience.comCategories: Cardiologists, Latest HeadlinesTweet-
Follow our science at https://t.co/E4bwYhx4sR #CVD #LDL #patientsfirst https://t.co/YvlQyrhrVk
-
-
Mashup Score: 0
Focused on significant, underserved population unable to maximize or tolerate statins Nearly 14,000 patients in 32 countries Nearly half of the patients were women Primary Endpoint (MACE-4) Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization Hierarchy of Secondary…
Source: esperionscience.comCategories: Cardiologists, Latest HeadlinesTweet-
Want to learn more about CLEAR Outcomes? check out our results @NEJM and at our website https://t.co/YUADQqX0ec #EsperionScience #CLEAROutcomes https://t.co/KC4GQll2di
-
-
Mashup Score: 0
Focused on significant, underserved population unable to maximize or tolerate statins Nearly 14,000 patients in 32 countries Nearly half of the patients were women Primary Endpoint (MACE-4) Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization Hierarchy of Secondary…
Source: esperionscience.comCategories: Cardiologists, Latest HeadlinesTweet-
That's a wrap on #ACC23! Great time in NOLA among some amazing minds who are working tirelessly to change the world. #CLEAROutcomes @EsperionInc @ACCinTouch @ClevelandClinic https://t.co/enBs4tsM27 https://t.co/IMwzh5oLLZ
-
-
Mashup Score: 1
Focused on significant, underserved population unable to maximize or tolerate statins Nearly 14,000 patients in 32 countries Nearly half of the patients were women Primary Endpoint (MACE-4) Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization Hierarchy of Secondary…
Source: esperionscience.comCategories: Cardiologists, Latest HeadlinesTweet-
Special thanks to Drs. Steven Nissen, @ProfSNicholls and Michael Lincoff for your trial leadership. @EsperionInc @ClevelandClinic #CLEAROutcomes https://t.co/YUADQqX0ec https://t.co/bRuA8LpmPT
-
-
Mashup Score: 2
Focused on significant, underserved population unable to maximize or tolerate statins Nearly 14,000 patients in 32 countries Nearly half of the patients were women Primary Endpoint (MACE-4) Composite of the time to first cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization Hierarchy of Secondary…
Source: esperionscience.comCategories: Cardiologists, Latest HeadlinesTweet-
Thankful to bring together the world’s experts in prevention and lipids! @ProfKausikRay @PamTaubMD @LaleTokgozoglu @larsulrich @DrDerekConnolly @MarcBonaca Wolfgang Koenig and Peter Libby together! Who have I missed? @CardioNerds #cardiotwitter #LDL https://t.co/YUADQqX0ec https://t.co/cTDVgruIWa
-
-
Mashup Score: 0CLEAR Program – Esperion Science - 1 year(s) ago
Importance Additional treatment options are needed for patients who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lipid-lowering therapies. Objective To assess the efficacy of bempedoic acid vs placebo in patients at high cardiovascular risk receiving maximally tolerated lipid-lowering therapy. Design, Setting, and…
Source: esperionscience.comCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/yDnqG1Rz93
-
Check out all of our science differentiating our oral LDL-c lowering therapies @CircAHA @AHAScience and at https://t.co/YWwMtGV9pr 🫀👏👏👏👏👏 #CLEAROutcomes https://t.co/xzi1LUdh0j